Compare SGHT & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHT | GEVO |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.6M | 340.8M |
| IPO Year | 2021 | 2010 |
| Metric | SGHT | GEVO |
|---|---|---|
| Price | $5.48 | $1.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.08 | $6.58 |
| AVG Volume (30 Days) | 186.8K | ★ 3.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.16 | ★ 58.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | $711,000.00 |
| Revenue This Year | $11.67 | $19.44 |
| Revenue Next Year | $10.39 | $5.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.11 | $1.12 |
| 52 Week High | $9.24 | $2.97 |
| Indicator | SGHT | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 39.30 |
| Support Level | $4.76 | $1.37 |
| Resistance Level | $5.66 | $1.57 |
| Average True Range (ATR) | 0.36 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 65.20 | 25.64 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.